Striatal Achyteneurons In Huntington'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Striatal achyteneurons (also known as aspiny neurons) are a population of GABAergic interneurons in the striatum that are selectively vulnerable in Huntington's disease (HD). These cholinergic interneurons, despite their relatively small numbers, play crucial roles in striatal function and show early dysfunction in HD.
The striatum contains several interneuron populations:
- Large cell bodies: 15-20 μm diameter
- Extensive dendritic arborization: Wide coverage of striatal volume
- Aspiny dendrites: Lack of dendritic spines (hence "ach_y_teneurons")
- Distribution: 1-3% of striatal neuronal population
- Parvalbumin-positive interneurons
- Somatostatin-positive interneurons
- Calretinin-positive interneurons
- ChAT: Choline acetyltransferase
- VAChT: Vesicular acetylcholine transporter
- p75NTR: Low-affinity NGF receptor
- TrkA: High-affinity NGF receptor
- Nicotinic receptors: α4β2, α6β2 subtypes
- Muscarinic receptors: M1-M5 subtypes
Striatal cholinergic interneurons (TANs):
- Provide tonic acetylcholine release
- Modulate dopamine release
- Integrate sensory information
- Coordinate motor learning
- Reward processing: Update learning signals
- Attention: Focus on relevant stimuli
- Motor timing: Sequence learning
- Habit formation: Reinforcement learning
In premanifest and early HD:
- Cholinergic interneurons show early dysfunction
- Reduced acetylcholine release
- Altered firing patterns
- Abnormal responses to dopamine
- Neuronal loss: Progressive degeneration of TANs
- Atrophy: Reduced cell size and dendritic complexity
- Inclusions: Mutant huntingtin aggregates (less prominent than in MSNs)
Why TANs are vulnerable in HD:
- High metabolic demands
- Calcium dysregulation
- Excitability patterns
- Mitochondrial sensitivity
- Imbalanced dopaminergic signaling
- Excessive cholinergic activity in early HD
- Progressive loss of modulatory capacity
- Altered corticostriatal inputs
- Disrupted thalamic integration
- Impaired intrastriatal communication
- Mutant huntingtin effects on transcription
- Impaired energy metabolism
- Oxidative stress
- Neuroinflammation
- Riluzole: Glutamate modulation
- Tetrabenazine: Dopamine depletion
- Antisense oligonucleotides: Huntingtin lowering (experimental)
- Muscarinic receptor modulators
- Acetylcholinesterase inhibitors (controversial)
- Nicotinic receptor agonists
- Gene therapy for mutant huntingtin
- Cell replacement therapy
- Neuroprotective compounds
The study of Striatal Achyteneurons In Huntington'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ferrante RJ, et al. J Neurosci. 1985 - Cholinergic neuron loss in HD
- Smith R, et al. Brain. 2006 - TAN dysfunction in HD
- Raymond LA, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2011 - Striatal interneurons
- Walker AG, et al. J Neurosci. 2018 - Cholinergic signaling in HD